[Catheter-directed thrombolytic therapy--a current alternative to proximal deep venous thrombosis].
Deep venous thrombosis extending into the iliac veins is associated with significant acute and late morbidity despite adequate conventional treatment with heparin and oral anticoagulants. The purpose of this paper is to focus on a multidisciplinary, aggressive approach with catheter-directed thrombolysis, in which a catheter with many side-holes is placed within the thrombus and thrombolytics infused. The aim is to eliminate the thrombus, to provide unobstructed venous drainage from the affected limb, and to prevent recurrent thrombosis. Total recanalisation of the iliofemoral segment was achieved in three of four treated patients, while partial lysis was obtained in one patient with symptoms for four weeks. Two weeks after discharge, two patients had no symptoms, while two had a moderate leg oedema. All of the three women used oral contraceptives at the time of thrombus formation; two had hereditary thrombophilia. Most probably, successful catheter-directed thrombolysis will reduce the incidence of post-thrombotic syndrome, but there are no long-term follow-up studies after such treatment.
Sandbaek
G
G
Radiologisk avdeling, Aker sykehus, Oslo.
Ly
B
B
Johansen
A M
AM
Rosales
A
A
D000328:Adult; D000368:Aged; D002408:Catheters, Indwelling; D003276:Contraceptives, Oral / Q000009:adverse effects; D000075202:Contraindications; D005260:Female; D005343:Fibrinolytic Agents / Q000008:administration & dosage*; D006493:Heparin / Q000008:administration & dosage; D006801:Humans; D007084:Iliac Vein / Q000000981:diagnostic imaging / Q000503:physiopathology; D008297:Male; D008875:Middle Aged; D011859:Radiography; D015912:Thrombolytic Therapy / Q000295:instrumentation / Q000379:methods*; D010959:Tissue Plasminogen Activator / Q000008:administration & dosage; D020246:Venous Thrombosis / Q000139:chemically induced / Q000188:drug therapy*; D014859:Warfarin / Q000008:administration & dosage
D003276:Contraceptives, Oral; D005343:Fibrinolytic Agents; D014859:Warfarin; D006493:Heparin; D010959:Tissue Plasminogen Activator